Login to Your Account



Allecra gets $24.7M to carry antibiotic through phase II

By Michael Fitzhugh
Staff Writer

Wednesday, June 15, 2016

Allecra Therapeutics GmbH has raised €22 million (US$24.7 million) in a series B round to fully fund phase II trials for AAI202, a combination of a beta-lactam antibiotic together with a proprietary, ESBL inhibitor designed to treat gram-negative multidrug-resistant bacterial infections.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription